Personalis, Inc. Overview
Pro stress-test →Personalis is a precision oncology genomics company that develops and markets advanced cancer genomic tests and liquid biopsy solutions. The company specializes in whole genome and exome sequencing combined with advanced analytics to deliver comprehensive insights into tumor genetics and immune response, supporting cancer detection, monitoring, and therapy development.
Strategic Profile
Pro stress-test →Personalis is positioned at the intersection of cancer diagnostics and personalized medicine, with differentiation through its whole genome sequencing approach and proprietary platforms like ImmunoID NeXT and NeXT Personal. The company leverages strategic partnerships with pharmaceutical giants and academic institutions to drive biomarker discovery and expand its addressable market in minimal residual disease (MRD) detection and precision cancer vaccine development.
Competitive Landscape
Pro stress-test →Personalis competes in the precision oncology genomics market against other liquid biopsy and cancer genomics companies. Its whole genome sequencing differentiation contrasts with exome-only competitors. Key competitive advantages include established CLIA-certified laboratory, partnerships with major pharma firms and VA Million Veterans Program, and proprietary algorithms for tumor microenvironment analysis.
Industry Context
Personalis, Inc. operates in Precision Oncology / Genomic Diagnostics.
Key facts
Headquarters: Fremont, California · Revenue: $65.0M (2022 annual)